Experimental Gerontology

Aging markers linked to gout progression and survival

After gout began, the highest versus lowest quarter for one aging measure had 1.41 years less average survival within ten years, before accounting for other factors.

Paper by Yu-Yao Mo, Rui-Ling Xu, Hui-Xuan Wu, Heng-Le Chen, Hou-De Zhou
Graphical abstract from Experimental Gerontology
Open the figure at full size
Graphical abstract. Mo et al., CC BY-NC-ND

Our read

Populations
Studied:
Cohort study of 502,128 UK Biobank participants, against the lowest quartiles
What changed:
Following gout onset, 10-year survival differed by −1.41 years comparing the highest with the lowest PhenoAge acceleration quartiles
The catch:
The ten-year survival comparison did not account for other health differences between participants
In the record:
The 532nd paper on PhenoAge with results in people; 1,224 on record in all. Its result on mortality agrees with 46 of 48 other findings on record; 2 point the other way.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

Among 502,128 UK Biobank participants, an observational analysis examined biological aging markers measured at baseline alongside blood urate, gout and survival. Urate is a waste product; high blood levels are called hyperuricemia. Gout is a form of arthritis.

In the primary adjusted model, higher PhenoAge acceleration—biological age running ahead of chronological age—was associated with higher urate and greater hazards of developing hyperuricemia or gout, progressing from hyperuricemia to gout, and dying after gout began. A second biological age measure showed similar associations, with smaller estimates for these future outcomes. Longer telomeres, the protective ends of chromosomes, were linked to lower urate and lower risk of developing gout. Across the range of telomere lengths, links to progression and later death were less clear.

Why it matters

Following gout through different stages broadens the question of how biological aging relates to disease: not just who develops it, but how it progresses and survival afterward.

Caveats

Participants with faster biological aging may also have had other health differences that contributed to gout progression and survival. The ten-year survival comparison did not account for such differences.

Comments

Be the first to comment.